sotorasib
amgen
['amg 510', 'sclc', 'lung', 'nsclc']
 in september 2019, the fda granted accelerated designation to amg 510 for the treatment of patients with previously treated metastatic non small cell lung cancer (nsclc) containing the kras g12c mutation.